Phase 1UnknownINTERVENTIONAL
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
ClinicalTrials.gov · NCT05328843 · Registry updated: 2022-04-14
- Condition / research focus
- Type2Diabetes
- Sponsor
- PegBio Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2022-05-01. Completion: 2022-10-01 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- PB119 (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Jia Miao
Chengdu, Sichuan, China
Site recruitment: Not reported